195 related articles for article (PubMed ID: 34920290)
1. Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management.
Vallerio P; Orenti A; Tosi F; Maistrello M; Palazzini M; Cingarlini S; Colombo P; Bertuzzi M; Spina F; Amatu A; Lombardo R; Prata I; Scaglione F; Vighi GD; Severgnini B; Siena S; Giannattasio C; Boracchi P; Sartore-Bianchi A
ESMO Open; 2022 Feb; 7(1):100338. PubMed ID: 34920290
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
[TBL] [Abstract][Full Text] [Related]
3. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis.
Qi WX; Shen Z; Tang LN; Yao Y
Crit Rev Oncol Hematol; 2014 Nov; 92(2):71-82. PubMed ID: 24878433
[TBL] [Abstract][Full Text] [Related]
4. Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
Furuya-Kanamori L; Doi SA; Onitilo A; Akhtar S
Expert Opin Drug Saf; 2020 Feb; 19(2):223-228. PubMed ID: 31698959
[No Abstract] [Full Text] [Related]
5. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients.
Liu B; Ding F; Liu Y; Xiong G; Lin T; He D; Zhang Y; Zhang D; Wei G
Oncotarget; 2016 Oct; 7(41):67661-67673. PubMed ID: 27602778
[TBL] [Abstract][Full Text] [Related]
6. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis.
Das A; Mahapatra S; Bandyopadhyay D; Samanta S; Chakraborty S; Philpotts LL; Jahangir E; Roy B
Crit Rev Oncol Hematol; 2021 Jan; 157():103186. PubMed ID: 33309571
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Schutz FA; Je Y; Richards CJ; Choueiri TK
J Clin Oncol; 2012 Mar; 30(8):871-7. PubMed ID: 22312105
[TBL] [Abstract][Full Text] [Related]
8. Risk of venous and arterial thromboembolic events associated with VEGFR-TKIs: a meta-analysis.
Liu B; Ding F; Zhang D; Wei GH
Cancer Chemother Pharmacol; 2017 Sep; 80(3):487-495. PubMed ID: 28695268
[TBL] [Abstract][Full Text] [Related]
9. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.
Qi WX; Sun YJ; Tang LN; Shen Z; Yao Y
Crit Rev Oncol Hematol; 2014 Mar; 89(3):394-403. PubMed ID: 24182420
[TBL] [Abstract][Full Text] [Related]
10. Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non-small-cell lung cancer: A PRISMA-compliant meta-analysis.
Lv WW; Zhang JJ; Zhou XL; Song Z; Wei CM
Medicine (Baltimore); 2019 Jun; 98(23):e15806. PubMed ID: 31169681
[TBL] [Abstract][Full Text] [Related]
11. Thyroid dysfunction related to vascular endothelial growth factor receptor tyrosine kinase inhibitors: A real-world study based on FAERS.
Liao X; Liu Z; Song H
J Clin Pharm Ther; 2021 Oct; 46(5):1418-1425. PubMed ID: 34169545
[TBL] [Abstract][Full Text] [Related]
12. Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors.
Dobbin SJH; Cameron AC; Petrie MC; Jones RJ; Touyz RM; Lang NN
Heart; 2018 Dec; 104(24):1995-2002. PubMed ID: 30228246
[TBL] [Abstract][Full Text] [Related]
13. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.
Qi WX; Shen Z; Tang LN; Yao Y
Br J Clin Pharmacol; 2014 Oct; 78(4):748-62. PubMed ID: 24661224
[TBL] [Abstract][Full Text] [Related]
14. Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid Cancer Treated With VEGFR TKIs.
Narayan V; Liu T; Song Y; Mitchell J; Sicks J; Gareen I; Sun L; Denduluri S; Fisher C; Manikowski J; Wojtowicz M; Vadakara J; Haas N; Margulies KB; Ky B
J Natl Compr Canc Netw; 2023 Oct; 21(10):1039-1049.e10. PubMed ID: 37856199
[TBL] [Abstract][Full Text] [Related]
15. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis.
Qi WX; Min DL; Shen Z; Sun YJ; Lin F; Tang LN; He AN; Yao Y
Int J Cancer; 2013 Jun; 132(12):2967-74. PubMed ID: 23225494
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials.
Li J; Gu J
Clin Drug Investig; 2018 Dec; 38(12):1109-1123. PubMed ID: 30327999
[TBL] [Abstract][Full Text] [Related]
17. Vascular Endothelial Growth Factor Receptor Inhibitors Impair Left Ventricular Diastolic Functions.
Yokoyama H; Shioyama W; Shintani T; Maeda S; Hirobe S; Maeda M; Sakata Y; Fujio Y
Int Heart J; 2021; 62(6):1297-1304. PubMed ID: 34853223
[TBL] [Abstract][Full Text] [Related]
18. Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?
Wang S; Yang Z; Wang Z
Oncotarget; 2015 Jul; 6(20):18206-23. PubMed ID: 26156021
[TBL] [Abstract][Full Text] [Related]
19. Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis.
Zhang ZF; Wang T; Liu LH; Guo HQ
PLoS One; 2014; 9(3):e90135. PubMed ID: 24621598
[TBL] [Abstract][Full Text] [Related]
20. Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin.
Patel SH; George TL; Wang TF; Vogt SM; Folefac E; Xu M; Yang Y; Parikh AB; Verschraegen CF; Clinton SK; Yin M
Cancer; 2021 Mar; 127(6):938-945. PubMed ID: 33216354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
